高鑫艳,黄俊玲

心血管疾病（CVD）是全球首要死亡原因，心血管疾病高危人群的早期识别与精准干预是降低全球疾病负担的关键。血脂异常是心血管疾病的重要危险因素，心血管高危人群的血脂筛查是动脉粥样硬化性心血管疾病（ASCVD）一级和二级预防的核心环节。传统血脂指标中低密度脂蛋白胆固醇（LDL-C）仍是心血管风险评估与干预的主要靶点但其对残余风险的预测存在局限因此一些新兴血脂指标成为了风险评估的重要补充。本综述系统分析了甘油三酯葡萄糖指数（TyG）、非高密度脂蛋白胆固醇（non-HDL-C）、载脂蛋白B（ApoB）、脂蛋白（a）[Lp（a）]以及其他血脂比值在心血管高危人群筛查中的临床价值及卫生经济学价值展开分析。

血脂指标；心血管疾病；高危人群；筛查；价值

[1] 刘明波,何新叶,杨晓红,等.《中国心血管健康与疾病报告2023》要点解读[J].临床心血管病杂志,2024,40(8):599-616. [2] Bashir B,Schofield J,Downie P,et al.Beyond LDL-C:unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia[J].Front Cardiovasc Med,2024,11:1389106. [3] Chamroonkiadtikun P,Ananchaisarp T,Wanichanon W.The triglyceride-glucose index,a predictor of type 2 diabetes development:A retrospective cohort study[J].Primary Care Diabetes,2020,14(2):161-167. [4] Ding X,Wang X,Wu J,et al.Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases:a meta-analysis of cohort studies[J].Cardiovascular diabetology,2021,20(1):76. [5] Liu Q,Cui H,Ma Y,et al.Triglyceride-glucose index associated with the risk of cardiovascular disease:the Kailuan study[J].Endocrine,2022:1-8. [6] Guerrero-Romero F,Simental-Mendía L E,González-Ortiz M,et al.The product of triglycerides and glucose,a simple measure of insulin sensitivity.Comparison with the euglycemic-hyperinsulinemic clamp[J].J Clin Endocrinol Metab,2010,95(7):3347-3351. [7] Nabipoorashrafi S A,Seyedi S A,Rabizadeh S,et al.The accuracy of triglyceride-glucose(TyG)index for the screening of metabolic syndrome in adults:a systematic review and meta-analysis[J].Nutrition,Metabolism and Cardiovascular Diseases,2022,32(12):2677-2688. [8] Cui C,Liu L,Qi Y,et al.Joint association of TyG index and high sensitivity C-reactive protein with cardiovascular disease:a national cohort study[J].Cardiovascular diabetology,2024,23(1):111-156. [9] Dang K,Wang X,Hu J,et al.The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease:NHANES 2003-2018[J].Cardiovasc Diabetol,2024,23(1):8. [10] Wilson P W F,Jacobson T A,Martin S S,et al.Lipid measurements in the management of cardiovascular diseases:Practical recom- mendations a scientific statement from the national lipid association writing group[J].Journal of clinical lipidology, 2021,15(5):629-648. [11] Johannesen C,Mortensen M B,Langsted A,et al.Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients[J].J Am Coll Cardiol,2021,77(11):1439-1450. [12] Wu F,Juonala M,Jacobs J D R,et al.Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events[J].Circulation(New York,N.Y.),2024,149(3):217-226. [13] 张丽沙,吴寿岭,邵郅强,等.非高密度脂蛋白胆固醇对绝经后女性心血管疾病的影响[J].中国循环杂志,2024,39(1):61-67. [14] Kohli-Lynch C N,Thanassoulis G,Moran A E,et al.The clinical utility of apoB versus LDL-C/non-HDL-C[J].Clinica chimica acta,2020, 508:103-108. [15] Aggarwal D J,Kathariya M G,Verma D P K.LDL-C,NON-HDL-C and APO-B for cardiovascular risk assessment:Looking for the ideal marker[J].Indian heart journal,2021,73(5):544-548. [16] Mach F,Baigent C,Catapano A L,et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk:The Task Force for the management of dyslipidaemias of the European Society of Cardiology(ESC)and European Atherosclerosis Society(EAS)[J].European heart journal,2020,41(1):111-188. [17] Pearson G J,Thanassoulis G,Anderson T J,et al.2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipi- demia for the Prevention of Cardiovascular Disease in Adults[J].Canadian journal of cardiology,2021,37(8):1129-1150. [18] 王增武,刘静,李建军,等.中国血脂管理指南（2023年）[J].中国循环杂志,2023,38(03):237-271. [19] 周文丽,王营忠.心血管风险评估的新兴标记物[J].临床医学进展,2022,12(10):9155-9161. [20] Su X,Wang M,Zuo Y,et al.Apolipoprotein Particle and Cardiovascular Risk Prediction(from a Prospective Cohort Study)[J].The American journal of cardiology,2023,201:34-41. [21] Marston N A,Giugliano R P,Melloni G,et al.Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis:Distinguishing Between Particle Concentration,Type,and Content[J].JAMA Cardiol,2022,7(3):250-256. [22] Huang Y,Chen S,Pan H,et al.Relationship between serum apolipoprotein B and risk of all-cause and cardiovascular disease mortality in individuals with hypertension:a prospective cohort study[J].BMC Cardiovasc Disord,2024,24(1):273. [23] Soffer D E,Marston N A,Maki K C,et al.Role of apolipoprotein B in the clinical management of cardiovascular risk in adults:An Expert Clinical Consensus from the National Lipid Association[J].Journal of clinical lipidology,2024,18(5):e647-e663. [24] Ramjee V,Sperling L S,Jacobson T A.Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification:Do the math[J].Journal of the American College of Cardiology,2011,58(5):457-463. [25] Cole J,Zubiran R,Wolska A,et al.Use of Apolipoprotein B in the Era of Precision Medicine:Time for a Paradigm Change?[J].J Clin Med,2023,12(17). [26] Luebbe S,Wilkins J,Moran A,et al.An Economic Evaluation of Non-HDL-Cholesterol and Apolipoprotein B as Treatment Targets for Lipid-Lowering Therapy in Primary Prevention[J].Circulation,2024,150(Suppl_1):A4142200. [27] Handhle A,Viljoen A,Wierzbicki A S.Elevated Lipoprotein(a):Background,Current Insights and Future Potential Therapies[J].Vascular health and risk management,2021,17:527-542. [28] Tsimikas S.Lipoprotein(a)in the Year 2024:A Look Back and a Look Ahead[J].Arteriosclerosis,thrombosis,and vascular biology, 2024,44(7):1485-1490. [29] Reyes-Soffer G,Ginsberg H N,Berglund L,et al.Lipoprotein(a):A Genetically Determined,Causal,and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease:A Scientific Statement From the American Heart Association[J].Arterioscler Thromb Vasc Biol,2022,42(1):e48-e60. [30] Patel A P,Wang M,Pirruccello J P,et al.Lp(a)(Lipoprotein[a])Concentrations and Incident Atherosclerotic Cardiovascular Disease:New Insights From a Large National Biobank[J].Arteriosclerosis,thrombosis,and vascular biology,2021,41(1):465-474. [31] 脂蛋白(a)与心血管疾病风险关系及临床管理的专家科学建议[J].中国循环杂志,2021,36(12):1158-1167. [32] Koschinsky M L,Bajaj A,Boffa M B,et al.A focused update to the 2019 NLA scientific statement on use of lipoprotein(a)in clinical practice[J].Journal of clinical lipidology,2024,18(3):e308-e319. [33] Bhatia H S,Hurst S,Desai P,et al.Lipoprotein(a)testing trends in a large academic health system in the United States[J].Journal of the American Heart Association,2023,12(18):e031255. [34] Ansari S,Garmany N R,Payne J,et al.The current status of lipoprotein(a)measurement in clinical biochemistry laboratories in the UK:Results of a 2021 national survey[J].Ann Clin Biochem,2024,61(3):195-203. [35] Sosnowska B,Surma S,Banach M.Targeted treatment against lipoprotein(a):the coming breakthrough in lipid lowering therapy[J]. Pharmaceuticals,2022,15(12):1573. [36] Sbrana F,Bigazzi F,Corciulo C,et al.Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a)subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy[J].Eur J Prev Cardiol,2024,31(8):e62-e64. [37] Adams J,Orfanos P,Hu X,et al.Review of Current Clinical Strategies of Managing Patients With Elevated Lipoprotein(a):Cost- Effectiveness of Lp(a)Testing and Patient Awareness of Lifestyle Changes Through Public Health Policy in Absence of a Targeted Therapy[J].Heart,Lung and Circulation,2024,33:S534. [38] Catapano A L,Tokgözoğlu L,Banach M,et al.Evaluation of lipoprotein(a)in the prevention and management of atherosclerotic cardiovascular disease:a survey among the Lipid Clinics Network[J].Atherosclerosis,2023,370:5-11. [39] Enas E A,Varkey B,Dharmarajan T S,et al.Lipoprotein(a):An independent,genetic,and causal factor for cardiovascular disease and acute myocardial infarction[J].Indian heart journal,2019,71(2):99-112. [40] Deng K,Pan X,Voehler M W,et al.Blood Lipids,Lipoproteins,and Apolipoproteins With Risk of Coronary Heart Disease:A Prospective Study Among Racially Diverse Populations[J].Journal of the American Heart Association,2024,13(10):e034364. [41] Zhang J,Song X,Li Z,et al.Association of apolipoprotein levels with all-cause and cardiovascular mortality[J].European journal of preventive cardiology,2024,31(9):1183-1194. [42] Che B,Zhong C,Zhang R,et al.Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors:an analysis of UK biobank data[J].Cardiovasc Diabetol,2023,22(1):34. [43] Khalili S,Amouzegar A,Dorost S S,et al.Assessing the predictive value of elevated triglycerides,triglyceride-glucose index(TyG),and TG/HDL ratios for cardiovascular disease and mortality during 20 years of follow-up:Tehran lipid and glucose study[J].Clinical Biochemistry,2025:110891. [44] Toprak K,Kaplangoray M,Akyol S,et al.The non-HDL-C/HDL-C ratio is a strong and independent predictor of the no-reflow phenomenon in patients with ST-elevation myocardial infarction[J].Acta Cardiologica,2024,79(2):194-205. [45] Liu C,Zhang Z,Meng T,et al.Cross-sectional analysis of non-HDL/HDL cholesterol ratio as a marker for cardiovascular disease risk in middle-aged and older adults:Evidence from the CHARLS study[J].Journal of Stroke and Cerebrovascular Diseases,2025,34(1):108168. [46] 中国血脂管理指南修订联合专家委员会,王增武,李建军,等.中国血脂管理指南（基层版2024年）[J].中国全科医学,2024,27(20):2429-2436. [47] Wu S,Xu L,Wu M,et al.Association between triglyceride-glucose index and risk of arterial stiffness:a cohort study[J].Cardiovasc Diabetol,2021,20(1):146. [48] Reyes-Soffer G,Ginsberg H N,Berglund L,et al.Lipoprotein(a):A Genetically Determined,Causal,and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease:A Scientific Statement From the American Heart Association[J].Arterioscler Thromb Vasc Biol,2022,42(1):e48-e60.

点击下载PDF